251 related articles for article (PubMed ID: 18383864)
1. Elevated serum-circulating RNA in patients with conventional renal cell cancer.
Feng G; Li G; Gentil-Perret A; Tostain J; Genin C
Anticancer Res; 2008; 28(1A):321-6. PubMed ID: 18383864
[TBL] [Abstract][Full Text] [Related]
2. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.
Urakami S; Shiina H; Enokida H; Hirata H; Kawamoto K; Kawakami T; Kikuno N; Tanaka Y; Majid S; Nakagawa M; Igawa M; Dahiya R
Clin Cancer Res; 2006 Dec; 12(23):6989-97. PubMed ID: 17145819
[TBL] [Abstract][Full Text] [Related]
3. Cell-free circulating DNA: Diagnostic value in patients with renal cell cancer.
Hauser S; Zahalka T; Ellinger J; Fechner G; Heukamp LC; VON Ruecker A; Müller SC; Bastian PJ
Anticancer Res; 2010 Jul; 30(7):2785-9. PubMed ID: 20683013
[TBL] [Abstract][Full Text] [Related]
4. Cathepsin D serum levels are not a valid serum marker in renal cell carcinoma.
Merseburger AS; Hennenlotter J; Stenzl A; Beger G; Rinnab L; Kuczyk MA; Kuefer R
Urol Int; 2007; 79(1):41-3. PubMed ID: 17627167
[TBL] [Abstract][Full Text] [Related]
5. Tissue expression and plasma levels of adrenomedullin in renal cancer patients.
Michelsen J; Thiesson H; Walter S; Ottosen PD; Skøtt O; Jensen BL
Clin Sci (Lond); 2006 Jul; 111(1):61-70. PubMed ID: 16515534
[TBL] [Abstract][Full Text] [Related]
6. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
Wechsel HW; Petri E; Bichler KH; Feil G
Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy.
Nisman B; Yutkin V; Nechushtan H; Gofrit ON; Peretz T; Gronowitz S; Pode D
Urology; 2010 Aug; 76(2):513.e1-6. PubMed ID: 20573390
[TBL] [Abstract][Full Text] [Related]
8. Application of SELDI-TOF-MS to identify serum biomarkers for renal cell carcinoma.
Xu G; Xiang CQ; Lu Y; Kang XN; Liao P; Ding Q; Zhang YF
Cancer Lett; 2009 Sep; 282(2):205-13. PubMed ID: 19362769
[TBL] [Abstract][Full Text] [Related]
9. Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies.
Ellinger J; Müller DC; Müller SC; Hauser S; Heukamp LC; von Ruecker A; Bastian PJ; Walgenbach-Brunagel G
Urol Oncol; 2012; 30(4):509-15. PubMed ID: 20870429
[TBL] [Abstract][Full Text] [Related]
10. Tissue polypeptide specific antigen (TPS) as a tumor marker in renal cell carcinoma.
Chang CH; Wu HC; Yen RF; Kao A; Lin CC; Lee CC
Anticancer Res; 2002; 22(5):2949-50. PubMed ID: 12530023
[TBL] [Abstract][Full Text] [Related]
11. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma.
Zhao A; Li G; Péoc'h M; Genin C; Gigante M
Exp Mol Pathol; 2013 Feb; 94(1):115-20. PubMed ID: 23064048
[TBL] [Abstract][Full Text] [Related]
12. Serum ferritin in renal cell carcinoma: effect of tumor size, volume grade, and stage.
Singh KJ; Singh SK; Suri A; Vijjan V; Goswami AK; Khullar M
Indian J Cancer; 2005; 42(4):197-200. PubMed ID: 16391438
[TBL] [Abstract][Full Text] [Related]
13. Detection of transcript for brain-type fatty Acid-binding protein in tumor and urine of patients with renal cell carcinoma.
Teratani T; Domoto T; Kuriki K; Kageyama T; Takayama T; Ishikawa A; Ozono S; Nozawa R
Urology; 2007 Feb; 69(2):236-40. PubMed ID: 17320655
[TBL] [Abstract][Full Text] [Related]
14. Circulating mitochondrial DNA in the serum of patients with testicular germ cell cancer as a novel noninvasive diagnostic biomarker.
Ellinger J; Albers P; Müller SC; von Ruecker A; Bastian PJ
BJU Int; 2009 Jul; 104(1):48-52. PubMed ID: 19154496
[TBL] [Abstract][Full Text] [Related]
15. Characterization of HLA-G expression in renal cell carcinoma.
Li BL; Lin A; Zhang XJ; Zhang X; Zhang JG; Wang Q; Zhou WJ; Chen HX; Wang TJ; Yan WH
Tissue Antigens; 2009 Sep; 74(3):213-21. PubMed ID: 19531101
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group.
Schips L; Dalpiaz O; Lipsky K; Langner C; Rehak P; Puerstner P; Pummer K; Zigeuner R
Eur Urol; 2007 Jan; 51(1):168-73; discussion 174. PubMed ID: 16844285
[TBL] [Abstract][Full Text] [Related]
17. Serum DNA hypermethylation in patients with kidney cancer: results of a prospective study.
Hauser S; Zahalka T; Fechner G; Müller SC; Ellinger J
Anticancer Res; 2013 Oct; 33(10):4651-6. PubMed ID: 24123044
[TBL] [Abstract][Full Text] [Related]
18. Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma.
Ramankulov A; Lein M; Johannsen M; Schrader M; Miller K; Loening SA; Jung K
Cancer Lett; 2008 Sep; 269(1):85-92. PubMed ID: 18504068
[TBL] [Abstract][Full Text] [Related]
19. Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer.
Flamini E; Mercatali L; Nanni O; Calistri D; Nunziatini R; Zoli W; Rosetti P; Gardini N; Lattuneddu A; Verdecchia GM; Amadori D
Clin Cancer Res; 2006 Dec; 12(23):6985-8. PubMed ID: 17145818
[TBL] [Abstract][Full Text] [Related]
20. Novel blood biomarkers of human urinary bladder cancer.
Osman I; Bajorin DF; Sun TT; Zhong H; Douglas D; Scattergood J; Zheng R; Han M; Marshall KW; Liew CC
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3374-80. PubMed ID: 16740760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
